

Recombinant Influenza Hemagglutinin (H7 Anhui) Full-Length Glycoprotein (rHA GP)

Catalog #: 1502-001

Lot #: 1510001

Description: Recombinant, Influenza Hemagglutinin Full-Length Glycoprotein (rHA GP) from virus strain A/Anhui/1/2013 (H7N9). Recombinant HA is supplied as an affinity purified protein. rHA is produced in Sf9 insect cells using baculovirus for expression and is purified by FPLC.


Storage: 2-3 weeks at -20°C, -80°C long term

Size: 50 µg of protein is supplied at a concentration of 0.293 mg/mL in Tris buffered saline plus 0.01% non-ionic detergent. The theoretical molecular weight of the protein is ~62 kDa, without glycosylation. Because of the highly glycosylated nature of this protein, migration in an SDS-PAGE gel is slowed resulting in broad, diffuse bands representing differing glycosylation forms.

Relevance: Recombinant hemagglutinin glycoprotein provides a control protein for immunoassays and a tool to enhance Orthomyxovirus research.


Western Blot: Quality control testing demonstrates strong detection of GP null under reduced conditions when using anti-H7N9 rabbit monoclonal antibody.

SDS-PAGE/Western Blot



(A) SDS-PAGE and stain demonstrating 1 µg and 5 µg (lanes 1 and 2, respectively) of rHA protein under denaturing and reducing conditions. (B) Western blot detection of rHA at 100 ng (lane 3) when detected with anti-H7N9 rabbit mAb at 0.5 µg/mL and an anti-rabbit IgG-HRP conjugate followed by TMB substrate.

Hemagglutination with Turkey Red Blood Cells: HA
 Titer 1:512



For additional influenza products, please visit:
<http://ibtbioservices.com/index.php/product-and-reagents/influenza-products>

Intended for research use only. Not for human, therapeutic, or diagnostic applications.
 The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of
 Integrated BioTherapeutics, Inc.

Copyright 2015. Integrated BioTherapeutics, Inc. All rights reserved